Insider Transactions in Q3 2022 at Lumos Pharma, Inc. (LUMO)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2022
|
Richard J Hawkins Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
208
+4.45%
|
$1,664
$8.8 P/Share
|
|
Sep 21
2022
|
Richard J Hawkins Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
2,214
+34.19%
|
$17,712
$8.84 P/Share
|
|
Sep 20
2022
|
Richard J Hawkins Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
1,506
+42.39%
|
$12,048
$8.75 P/Share
|
|
Sep 19
2022
|
Richard J Hawkins Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
541
+50.0%
|
$4,328
$8.65 P/Share
|
|
Sep 01
2022
|
David B Karpf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
570
-7.22%
|
$4,560
$8.53 P/Share
|
|
Aug 25
2022
|
Thomas A. Raffin Director |
BUY
Open market or private purchase
|
Direct |
1,150
+10.89%
|
$9,200
$8.46 P/Share
|
|
Aug 25
2022
|
Joseph S Mc Cracken Director |
BUY
Open market or private purchase
|
Direct |
3,170
+21.29%
|
$25,360
$8.6 P/Share
|
|
Aug 02
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,407
-12.16%
|
$27,256
$8.11 P/Share
|
|
Aug 01
2022
|
John C. Mc Kew Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,593
-5.38%
|
$12,744
$8.17 P/Share
|
|
Aug 01
2022
|
Lori D Lawley Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-2.21%
|
$1,832
$8.17 P/Share
|